PCSK9 and infection: A potentially useful or dangerous association?-Reference-Cited by-同舟云学术

PCSK9 and infection: A potentially useful or dangerous association?

Published:2017-07-04 Issue:4 Volume:233 Page:2920-2927
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J Cell Physiol

Author:

Khademi Farzad¹,Momtazi-borojeni Amir Abbas²³,Reiner Željko⁴,Banach Maciej⁵⁶,Al-Rasadi Khalid Al⁷,Sahebkar Amirhossein⁸⁹^ORCID

Affiliation:

1. Department of Microbiology; School of Medicine, Ardabil University of Medical Sciences; Ardabil Iran

2. Nanotechnology Research Center; Bu-Ali Research Institute; Mashhad University of Medical Sciences; Mashhad Iran

3. Faculty of Medicine; Department of Medical Biotechnology; Student Research Committee; Mashhad University of Medical Sciences; Mashhad Iran

4. Department of Internal Medicine; University Hospital Centre Zagreb; School of Medicine University of Zagreb; Zagreb Croatia

5. Department of Hypertension; WAM University Hospital in Lodz; Medical University of Lodz; Lodz Poland

6. Polish Mother's Memorial Hospital Research Institute (PMMHRI); Lodz Poland

7. Department of Clinical Biochemistry; Sultan Qaboos University Hospital; Muscat Oman

8. Biotechnology Research Center; Mashhad University of Medical Sciences; Mashhad Iran

9. School of Medicine; University of Western Australia; Perth Australia

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Reference62 articles.

1. ESC/EAS guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the european society of cardiology (ESC) and european atherosclerosis society (EAS) developed with the special contribution of the european assocciation for cardiovascular prevention & rehabilitation (EACPR);Authors/Task Force;Atherosclerosis,2016

2. Lipids, blood pressure and kidney update 2014;Banach;Pharmacological Research,2015

3. A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients;Banach;Pharmacological Research,2016

4. PoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016;Banach;Archives of Medical Science,2017

5. Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established Coronary heart disease (from the phase 2 EQUATOR study);Baruch;The American Journal of Cardiology,2017

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCSK9 inhibition: from effectiveness to cost-effectiveness;Frontiers in Cardiovascular Medicine;2024-06-25

2. Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection;Microbial Cell Factories;2024-03-25

3. Meta-GWAS on PCSK9 concentrations reveals associations of novel loci outside the PCSK9 locus in White populations;Atherosclerosis;2023-12

4. The Association Between PCSK9 Inhibitor Use and Sepsis: A Systematic Review and Meta-Analysis of 20 Double-Blind, Randomized, Placebo-Controlled Trials;The American Journal of Medicine;2023-06

5. Insight into the Evolving Role of PCSK9;Metabolites;2022-03-17